According to the World Health Organization (WHO), the American tropics have been reinfested with Aedes aegypti, the mosquito known to carry arboviruses such as Yellow Fever. Most urban dwellers are vulnerable because of low immunization coverage and Latin America is now at greater risk of epidemics than at any time in the past 50 years. The BioFront Technologies line of anti-Yellow Fever virus monoclonal antibodies have been demonstratrd to produce reliable and trusted results for researchers leading the fight against this global issue.